Compounds having the formula (I),
Ar--(F)-(E)-(CR.sup.3R.sup.4)--(CHR.sup.5).sub.m-(T)-(Q)-Ar.sup.1, are
useful as CCR-3 receptor antagonists, wherein T is a bridged heterocyclyl
group having one N atom and a bridge of one to two bridgehead carbon
atoms; Ar and Ar.sup.1 are aryl or heteroaryl; F is alkylene, alkenylene,
or a bond; E is --C(.dbd.O)N(R.sup.10)--, --SO.sub.2N(R.sup.10)--,
--N(R.sup.11)C(.dbd.O)N(R.sup.10)--, --N(R.sup.11)SO.sub.2N(R.sup.10)--,
--N(R.sup.11)C(.dbd.S)N(R.sup.10)--, --N(R.sup.11)C(.dbd.O)--,
--N(R.sup.11)SO.sub.2--, --N(R.sup.12)C(.dbd.O)CH(R.sup.13)--, or
CH(R.sup.13)C(.dbd.O)N(R.sup.12)--; Q is --C(.dbd.O)-- or
C.sub.1-2alkylene; and R.sup.3, R.sup.4, R.sup.5, R.sup.9, R.sup.10,
R.sup.11, R.sup.12, and R.sup.13 are defined as set forth in the
specification.
